AGL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Agilon Health (AGL) is not a strong buy for a beginner, long-term investor at this time. The company is facing financial challenges, legal issues, and bearish technical indicators. While there is some hedge fund interest and potential for sector recovery, these factors are outweighed by the negative catalysts and weak financial performance.
The stock is in a bearish trend with the MACD histogram at -0.06 and negatively expanding, RSI at 7.452 indicating oversold conditions, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). Key support levels are at 0.405 and 0.273, with resistance at 0.83 and 0.962.
Hedge funds are significantly increasing their buying activity (+1326.49% last quarter). Analysts see potential for sector recovery driven by the new LEAD ACO model.
Multiple class action lawsuits alleging false statements and securities violations. Financial performance is deteriorating with declining revenue, net income, and EPS. Analysts have downgraded price targets, and insider trading trends are neutral.
In Q3 2025, revenue decreased by -1.08% YoY to $1.435 billion, net income dropped by -6.30% YoY to -$110.2 million, and EPS fell by -6.90% YoY to -0.27. Gross margin improved slightly by 1.66% YoY but remains negative at -4.29.
Analysts are mixed on AGL. Jefferies views the new LEAD ACO model as a positive for the sector but maintains a Hold rating on AGL. Bernstein lowered its price target to 88c from $1.40 due to high medical costs and market exits, while RBC Capital upgraded AGL Energy (unrelated to Agilon Health) citing unrelated factors.
